Gilead Sciences to Appoint John C Martin as New Chairman

Gilead Sciences has announced that executive chairman John Martin, PhD will transition from his current role of executive chairman to chairman of the board of directors effective March 9, 2018. Dr. Martin was named Executive Chairman on March 10, 2016, when he was succeeded as CEO by John Milligan, PhD. Dr. Martin served as chief executive officer of Gilead from 1996 to 2016, having joined the company in 1990 as the vice president of research and development. During his time as CEO, he built the company's portfolio to 24 marketed products with annual revenues of more than USD 32 billion.

"John's scientific and business leadership has been notable for the development of Gilead's portfolio of HIV and viral hepatitis medicines and commitment to worldwide access for patients. We are all grateful that he will continue to help guide the company as chairman of the board," said Dr. Milligan, president and chief executive officer of Gilead.